Treatment of Hyperthyroidism Reduces Systemic Oxidative Stress, as Measured by Markers of RNA and DNA Damage

J Clin Endocrinol Metab. 2021 Jun 16;106(7):e2512-e2520. doi: 10.1210/clinem/dgab273.

Abstract

Background: Whole-body oxidative stress can be estimated by the urine excretion of oxidized guanosine species, 8-oxo-7,8-dihydroguanosine (8-oxoGuo) and 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), derived from RNA and DNA, respectively. These oxidative stress markers are not well explored in thyroid disorders.

Objective: We aimed to determine whether treatment of hyperthyroid patients affects the levels of these oxidative stress markers.

Methods: Urinary excretion of 8-oxoGuo and 8-oxodG was measured in 51 hyperthyroid patients (toxic nodular goiter [TNG], n = 30; Graves disease [GD], n = 21) before or shortly after initiation of therapy and when stable euthyroidism had been achieved for at least 12 months.

Results: Adjusting for age, the baseline urinary excretion of oxidative stress markers correlated positively with plasma thyroxine (8-oxoGuo, P = 0.002; 8-oxodG, P = 0.021) and was significantly higher in GD than in TNG patients (P = 0.001 for both oxidative stress markers). Restoration of euthyroidism significantly affected the excretion of the oxidative stress markers. In TNG, 8-oxoGuo decreased from geometric mean 2.11 nmol/mmol creatinine (95% CI, 1.85-2.39) to 1.91 nmol/mmol (95% CI, 1.67-2.19; P = 0.001), while 8-oxodG decreased from 1.65 nmol/mmol (95% CI, 1.41-1.93) to 1.48 nmol/mmol (95% CI, 1.27-1.74; P = 0.026). In GD, 8-oxoGuo decreased from 2.25 nmol/mmol (95% CI, 1.95-2.59) to 1.79 nmol/mmol (95% CI, 1.63-1.97; P = 0.0003), while 8-oxodG decreased from 2.02 nmol/mmol (95% CI, 1.73-2.38) to 1.54 nmol/mmol (95% CI, 1.31-1.81; P = 0.001). In the euthyroid state, there were no differences between groups.

Conclusion: Restoration of euthyroidism in patients with hyperthyroidism significantly decreased the systemic oxidative stress load by 10% to 25%. Our findings may help to explain the higher morbidity and mortality linked to hyperthyroid diseases, as shown in observational studies.

Trial registration: ClinicalTrials.gov NCT02005250.

Keywords: 8-oxo-7,8-dihydro-2’-deoxyguanosine; 8-oxo-7,8-dihydroguanosine; Graves disease; hyperthyroidism; oxidative stress; toxic nodular goiter.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8-Hydroxy-2'-Deoxyguanosine / urine
  • Adult
  • Aged
  • Aged, 80 and over
  • Antithyroid Agents / therapeutic use*
  • Biomarkers / urine
  • DNA Damage
  • Female
  • Guanosine / analogs & derivatives
  • Guanosine / urine
  • Humans
  • Hyperthyroidism / blood
  • Hyperthyroidism / drug therapy*
  • Hyperthyroidism / urine*
  • Middle Aged
  • Oxidative Stress*
  • Prospective Studies
  • Thyroxine / blood
  • Treatment Outcome
  • Young Adult

Substances

  • Antithyroid Agents
  • Biomarkers
  • Guanosine
  • 8-hydroxyguanosine
  • 8-Hydroxy-2'-Deoxyguanosine
  • Thyroxine

Associated data

  • ClinicalTrials.gov/NCT02005250